Man Group
LCTX icon

Man Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Man Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-102,396
Closed -$143K – 1877
2022
Q4 		$120K Buy
+102,396
New +$129K ﹤0.01% 1884
2021
Q1 		– Sell
-23,788
Closed -$42K – 1931
2020
Q4 		$42K Buy
+23,788
New +$33.3K ﹤0.01% 1795

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's LCTX Position: Q1 2023 in Review

Man Group sold out of Lineage Cell Therapeutics (LCTX) in Q1 2023, closing a stake of 102,396 shares — an estimated $143K sold.

Man Group first reported a position in LCTX in Q4 2020 and held it in 2 quarters. The position peaked at $120K in Q4 2022. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • Man Group reported no remaining Lineage Cell Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 102,396 Lineage Cell Therapeutics shares in Q1 2023, an estimated $143K.
  • Man Group first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 2 quarters.
  • Man Group's Lineage Cell Therapeutics position peaked at $120K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.